KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Other Non Operating Income (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Other Non Operating Income data on record, last reported at -$12.0 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 394.93% year-over-year to -$12.0 million; the TTM value through Sep 2025 reached $16.1 million, up 239.93%, while the annual FY2024 figure was $23.8 million, N/A changed from the prior year.
  • Other Non Operating Income reached -$12.0 million in Q4 2025 per PACB's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $6.9 million in Q1 2023 and bottomed at -$24.3 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is -$600250.0, with a median of $112500.0 recorded in 2021.
  • Peak YoY movement for Other Non Operating Income: tumbled 535.94% in 2022, then skyrocketed 2561.29% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $1000.0 in 2021, then surged by 2200.0% to $23000.0 in 2022, then crashed by 105756.52% to -$24.3 million in 2023, then surged by 116.73% to $4.1 million in 2024, then crashed by 394.93% to -$12.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$12.0 million in Q4 2025, $3.0 million in Q3 2025, and $4.7 million in Q2 2025.